Nilotinib Eg Labo

Nilotinib, the active ingredient in Nilotinib Eg Labo, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of chronic myeloid leukemia, particularly in adult patients with Philadelphia chromosome‑positive disease.

GNH USA supplies Nilotinib Eg Labo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and consistent product availability across markets.

Nilotinib targets the BCR‑ABL tyrosine kinase pathway and is indicated for specific phases of chronic myeloid leukemia.

- Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and achieves hematologic and cytogenetic responses. - Chronic myeloid leukemia (accelerated phase): helps attain disease control and improves survival outcomes. - Chronic myeloid leukemia (blast phase): used to achieve remission in advanced disease stages.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools often transient. - Rash: skin erythema or pruritus. - Headache: mild cranial discomfort. - Fatigue: generalized tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Severe thrombocytopenia: low platelet levels causing bleeding. - Cardiac failure: reduced heart function presenting with dyspnea.

Before initiating therapy, clinicians should assess several safety parameters. - Cardiac monitoring: obtain baseline ECG and monitor QT interval during therapy. - Liver function: assess hepatic enzymes before and periodically while on treatment. - Pancreatic enzymes: check amylase and lipase levels regularly. - Hematologic parameters: monitor complete blood count for neutropenia or thrombocytopenia. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors and QT‑prolonging agents. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Nilotinib has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone, sotalol): raise risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may require dose adjustment. - CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower nilotinib plasma levels. - Warfarin: may enhance anticoagulant effect, monitor INR. - Digoxin: potential increase in serum concentration, monitor levels. - St. John’s wort: may reduce efficacy, advise discontinuation.